NASDAQ:TBPH Theravance Biopharma Q2 2026 Earnings Results & Report $17.03 0.00 (0.00%) As of 11/6/2026 Theravance Biopharma missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.11 versus the $0.0725 consensus estimate, while revenue of $20.73 million fell short of the $22.49 million estimate by $1.76 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 10, 2026TimeBefore Market OpensConference Call8:30 AM ET Theravance Biopharma EPS ResultsActual EPS-$0.11Consensus EPS $0.0725Beat/MissMissed by -$0.1825One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersTheravance Biopharma Revenue ResultsActual Revenue$20.73 millionExpected Revenue$22.49 millionBeat/MissMissed by -$1.76 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Theravance Biopharma Q2 2026 Earnings FAQ Did Theravance Biopharma beat earnings estimates for Q2 2026? Theravance Biopharma (NASDAQ:TBPH) reported earnings of -$0.11 per share for Q2 2026, missing the consensus estimate of $0.0725. The report was announced on Monday, August 10, 2026. What was Theravance Biopharma's revenue for Q2 2026? Theravance Biopharma reported revenue of $20.73 million for Q2 2026, against a consensus estimate of $22.49 million. Theravance Biopharma Earnings HeadlinesTheravance Biopharma, Inc. (NASDAQ:TBPH) Stock Has Average Target Price of $19.00November 16, 2026 | americanbankingnews.comTheravance Biopharma (TBPH) Set to Release Earnings on TuesdayNovember 9, 2026 | americanbankingnews.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 20 at 1:00 AM | Behind the Markets (Ad)Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness IndexSeptember 24, 2026 | marketscreener.comMZymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.September 24, 2026 | de.marketscreener.comDTheravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P TMI IndexSeptember 23, 2026 | marketscreener.comMSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for the maintenance of chronic obstructive pulmonary disease (COPD) in adults. In the United States, the product is commercialized through a collaboration with Viatris. The company was established as an independent business following its separation from Theravance, Inc. in 2014. Its research and development work has included therapies for respiratory and other serious conditions. Theravance Biopharma is led by Chief Executive Officer Rick E. Winningham.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.